Vinorelbine and Bevacizumab in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Part of paid clinical trials in Rochester, New York.

Sponsor
University of Rochester
Study ID
NCT00309998
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
70 Years - 120 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Drugs used in chemotherapy, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving vinorelbine together with bevacizumab may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving vinorelbine together with bevacizumab works in treating older patients with stage III or stage IV non-small cell lung cancer.

Key Dates

Start date
Sep 30, 2005
Status verified
Oct 2024
Primary completion
May 31, 2007

Study Design

Enrollment
50 participants (estimated)
Primary purpose
TREATMENT

Primary Outcome Measure

Median time to disease progression by imaging study every 6 weeks

Locations (1)

FacilityCityStateZIPSite coordinators
James P. Wilmot Cancer Center at University of Rochester Medical CenterRochesterNew York14642-0001-

Find similar trials in Rochester, NY

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
James P. Wilmot Cancer Center at University of Rochester Medical Center· Rochester, NY

Related Studies